ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Decibel raises $55 million for hearing loss

by Ryan Cross
June 24, 2018 | APPEARED IN VOLUME 96, ISSUE 26

Boston-based Decibel Therapeutics has raised $55 million in series C financing to continue developing therapies to treat hearing loss and tinnitus. The start-up is working on two compounds to protect against hearing loss that is a side effect of other drugs and on a gene therapy to restore hearing. George Scangos, CEO of Vir Biotechnology and former CEO of Biogen, now heads Decibel’s board of directors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment